According to the <a href="assets.ctfassets.net report</a>, during the 2019 financial year, Amcor's net cash provided by operating activities was US$776.1 million, a fall from US$871.4 million recorded in the prior year. Net cash provided by investing activities in 2019 was US$10.2 million against a net used in 2018 of US$241.9 million. Net cash used in financing activities in 2019 was US$764.9 million against a net cash used in 2018 of US$542.7 million. Cash and cash equivalents at the end of 2019 were US$601.6 million, a fall from US$620.8 million recorded at the end of the 2018 financial year.&nbsp;

The Amcor 2019 publications reflect an 89% year-on-year asset growth to US$17.1 billion (2018: US$9.1 billion). Cash and liquid assets declined 3% year-on-year to US$601.6 million (2018: US$620.8 million). Current assets increased 44% year-on-year to US$5.2 billion (2018: US$3.6 million) while non-current assets increased 122% to US$12 billion (2018: US$5.4 billion). The shareholders' equity increased significantly year-on-year to US$5.7 billion (2018: US$695.4 million).

The 2019 Amcor PLC <a href="assets.ctfassets.net publications</a> reflect a 2% year-on-year net sales growth to US$9.5 billion in 2019 and a 2% growth in 2018 against 2017 (2018: US$9.3 billion, 2017: US$9.1 billion). Gross profit declined year-on-year to US$1.8 billion in 2019 (2018: US$1.9 billion, 2017: US$1.9 billion). Operating income declined 20% year-on-year to US$791.7 million in 2019 and an 8.5% year-on-year growth to US$993.9 million recorded in 2018 from US$916.1 million recorded in 2017. Income from continuing operations declined 25% year-on-year to US$437.4 million in 2019 and increased 1% year-on-year in 2018 to US$586.6 million from US$581 million in 2017.&nbsp;

The AstraZeneca <a href="www.astrazeneca.com reflect a 2% year-on-year revenue fall to US$22.1 billion (2017: US$22.5 billion, 2016: US$23 billion). Reported operating profit declined 8% year-on-year to US$3.4 billion (2017: US$3.7 billion, 2016: US$4.1 billion). Reported earnings per share declined from US$2.37 in 2017 to US$1.7. Net cash flow from operating activities declined 27% year-on-year to US$2.6 billion (2017: US$3.6 billion, 2016: US$4.1 billion). Core operating profit declined 17% year-on-year to US$5.7 billion (2017: US$6.9 billion, 2016: US$6.7 billion). Core earnings per share declined 19% year-on-year to US$3.46 (2017: US$4.28, 2016: US$4.31).

The Astrazeneca <a href="www.astrazeneca.com reflect a 2% year-on-year revenue fall to US$22.090 billion in 2018 (2017: US$22.465 billion, 2016: US$23.002 billion). This includes product sales of US$21.049 billion which increased year-on-year by 4% and externalization revenue of US$1.041 billion which declined year-on-year by 55%.&nbsp;

For the twelve months ended 30 April 2019, the Cohort 2019 <a href="www.cohortplc.com reflect a 27% asset growth to GBP148.449 million against GBP116.459 million recorded in the prior twelve months. Cash and liquid assets declined 8% year-on-year to GBP18.8 million (2018: GBP20.5 million). Non-current assets increased 32% to GBP73.3 million (2018: GBP55.3 million whereas current assets increased 23% to GBP75.2 million (2018: GBP61.1 million). Net assets increased 2.7% to GBP77 million (2018: GBP75 million). The equity to asset ratio was 51% (2018: 64%).

According to the <a href="www.cohortplc.com report</a>, the Board recommended a final dividend of 6.25 pence per ordinary share (2018: 5.65 pence) for the 2019 financial year, making a total dividend of 9.10 pence per ordinary share (2018: 8.20 pence), an 11% year-on-year increase. This is to be paid on 18 September 2019 subject to approval at the Annual General Meeting on 17 September 2019.

The Cohort 2019 <a href="www.cohortplc.com publications</a> reflect a closing net debt of GBP6.4 million (2018: net funds of GBP11.3million). The GBP16.2 million (2018: GBP15.2 million) of adjusted operating profit and an overall working capital outflow resulting in GBP11.6 million (2018: GBP15.1 million inflow) operating cash flow. The operating cash inflow was utilized in paying tax, dividends and capital investments, a total outflow of GBP8.2 million (2018: GBP5.5 million).

According to the annual report, underlying earnings per share for the 2018 financial year increased 2% to 42.9 pence (2017: 42.1 pence). Basic earnings per share were 31.3 pence (2017: 26.0 pence).

For the twelve months ended 31 December 2018, the Bae Systems <a href="investors.baesystems.com publications</a> indicate a sales fall by GBP0.1 billion to GBP18.4 billion from GBP18.5 billion reported in the prior twelve months ended 31 December 2017. Underlying EBITDA decreased by GBP46 million to GBP1.928 billion (2017: GBP1.974 billion) giving a return on sales of 10.5% (2017: 10.7%). Revenue declined by GBP0.4 billion to GBP16.8 billion (2017: GBP17.2 billion). Operating profit increased by GBP186 million to GBP1.605 billion (2017: GBP1.419 billion). Operating business cash flow was GBP993 million against GBP1.752 billion in 2017. Net debt was GBP904 million against GBP752 million in 2017. Basic earnings per share were 31.3 pence against 26.0 pence in 2017.&nbsp;